A股異動 | 海思科升停 股價創逾2年新高 HSK38008口服制劑獲批開展用於治療“前列腺癌”的臨牀試驗
格隆匯4月7日丨海思科升停,報27.6元,總市值307億元,股價創逾2年新高。海思科(002653.SZ)公佈,公司於近日獲得國家藥品監督管理局藥品審評中心下發的《藥物臨牀試驗批准通知書》,藥品名稱為HSK38008。根據《中華人民共和國藥品管理法》及有關規定,經審查,HSK38008口服制劑符合藥品註冊的有關要求,同意本品開展用於治療“前列腺癌”的臨牀試驗。HSK38008是公司自主研發的全球首家口服AR-V7降解劑,擬用於前列腺癌的治療。按我國新化學藥品註冊分類規定,其藥品註冊分類為化藥1類。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.